Associated Papers
Integrated pathway analysis identifies prognostically relevant subtypes of glioblastoma characterized by abnormalities in multi-omics.
Zhang P et al.
Clinical and Translational Medicine, 2025
Identifying active and inhibitor-resistant MGMT variants for gene therapy.
Cheong A et al.
American Journal of Human Genetics, 2025
IDH1 and ATRX mutations synergistically modulate cell proliferation and ferroptosis in glioblastoma cells.
Liu S et al.
American Journal of Cancer Research, 2025
Integrating molecular profiling into glioma diagnosis: implications of the WHO-CNS5-2021 classification of adult-type diffuse gliomas in Colombian patients.
Echeverría O et al.
Frontiers in Neurology, 2025
Multiplex single-cell chemical genomics reveals the kinase dependence of the response to targeted therapy.
McFaline-Figueroa JL et al.
Cell Genomics, 2024
Targeting the non-coding genome and temozolomide signature enables CRISPR-mediated glioma oncolysis.
Tan IL et al.
Cell Reports, 2023
WNT signaling modulates chemoresistance to temozolomide in p53-mutant glioblastoma multiforme.
Ma Z et al.
Apoptosis : an International Journal on Programmed Cell Death, 2022
Discrimination between 34 of 36 Possible Combinations of Three C>T SNP Genotypes in the MGMT Promoter by High Resolution Melting Analysis Coupled with Pyrosequencing Using A Single Primer Set.
Zappe K et al.
International Journal of Molecular Sciences, 2021
Transcriptional Pausing and Activation at Exons-1 and -2, Respectively, Mediate the MGMT Gene Expression in Human Glioblastoma Cells.
Al-Obaide MAI et al.
Genes, 2021
Cancer-specific loss of TERT activation sensitizes glioblastoma to DNA damage.
Amen AM et al.
Proceedings of the National Academy of Sciences of the United States of America, 2021
Genomic Space of MGMT in Human Glioma Revisited: Novel Motifs, Regulatory RNAs, NRF1, 2, and CTCF Involvement in Gene Expression.
Ibrahim Al-Obaide MA et al.
International Journal of Molecular Sciences, 2021
Heat Shock Protein Inhibitor 17-Allyamino-17-Demethoxygeldanamycin, a Potent Inductor of Apoptosis in Human Glioma Tumor Cell Lines, Is a Weak Substrate for ABCB1 and ABCG2 Transporters.
Pastvova N et al.
Pharmaceuticals (basel, Switzerland), 2021
A novel Cas9-targeted long-read assay for simultaneous detection of IDH1/2 mutations and clinically relevant MGMT methylation in fresh biopsies of diffuse glioma.
Wongsurawat T et al.
Acta Neuropathologica Communications, 2020
MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas.
Abe H et al.
Frontiers in Oncology, 2019
The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.
Durant ST et al.
Science Advances, 2018
S-phase Specific Downregulation of Human O6-Methylguanine DNA Methyltransferase (MGMT) and its Serendipitous Interactions with PCNA and p21cip1 Proteins in Glioma Cells.
Mostofa A et al.
Neoplasia (new York, N.y.), 2018
Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma.
Braun CJ et al.
Cancer Cell, 2017
Synergistic cooperation and crosstalk between MYD88L265P and mutations that dysregulate CD79B and surface IgM.
Wang JQ et al.
The Journal of Experimental Medicine, 2017
Integrated genomic analyses of de novo pathways underlying atypical meningiomas.
Harmancı AS et al.
Nature Communications, 2017
Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status.
Patyka M et al.
Oncotarget, 2016
Opposing roles of glutaminase isoforms in determining glioblastoma cell phenotype.
Szeliga M et al.
Neurochemistry International, 2015
Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide.
McFaline-Figueroa JL et al.
Cancer Research, 2015
Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).
Cabrini G et al.
International Journal of Oncology, 2015
Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth.
Ramirez YP et al.
Molecular Cancer Therapeutics, 2015
FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents.
Patil AA et al.
Oncotarget, 2014
The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.
Moen EL et al.
Molecular Cancer Therapeutics, 2014
Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.
Wang X et al.
Annals of Surgical Oncology, 2014
TDP1 deficiency sensitizes human cells to base damage via distinct topoisomerase I and PARP mechanisms with potential applications for cancer therapy.
Alagoz M et al.
Nucleic Acids Research, 2014
Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase.
Wang X et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2013
In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing.
Kreth S et al.
Acta Neuropathologica, 2013
Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas.
Chiang MF et al.
Frontiers in Oncology, 2013
Transfection of a human glioblastoma cell line with liver-type glutaminase (LGA) down-regulates the expression of DNA-repair gene MGMT and sensitizes the cells to alkylating agents.
Szeliga M et al.
Journal of Neurochemistry, 2012
Activated leukocyte cell adhesion molecule is expressed in neuroepithelial neoplasms and decreases with tumor malignancy, matrix metalloproteinase 2 expression, and absence of IDH1R132H mutation.
Allmendinger O et al.
Human Pathology, 2012
The human RECQ1 helicase is highly expressed in glioblastoma and plays an important role in tumor cell proliferation.
Mendoza-Maldonado R et al.
Molecular Cancer, 2011
The A/G allele of rs16906252 predicts for MGMT methylation and is selectively silenced in premalignant lesions from smokers and in lung adenocarcinomas.
Leng S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status.
Nagane M et al.
Journal of Neuro-oncology, 2009
The Mre11/Rad50/Nbs1 complex interacts with the mismatch repair system and contributes to temozolomide-induced G2 arrest and cytotoxicity.
Mirzoeva OK et al.
Molecular Cancer Therapeutics, 2006
DNA repair gene O6-methylguanine-DNA methyltransferase: promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors.
Yin D et al.
Molecular Carcinogenesis, 2003